Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Insulet (PODD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Insulet (PODD – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vertex Pharmaceuticals (VRTX)
In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $530.00. The company’s shares closed last Wednesday at $470.31.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $547.20, a 15.5% upside from current levels. In a report issued on February 13, Oppenheimer also upgraded the stock to Buy with a $540.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Insulet (PODD)
Jefferies analyst Matthew Taylor reiterated a Buy rating on Insulet today and set a price target of $400.00. The company’s shares closed last Wednesday at $258.07.
According to TipRanks.com, Taylor is a 4-star analyst with an average return of
Insulet has an analyst consensus of Strong Buy, with a price target consensus of $353.47, implying a 32.9% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $285.00 price target.
